Dyne Therapeutics to Present at the 2025 MDA Conference
- Highlighting Key Data from Recent Clinical Trials -
- Insights on Splicing Correction as a Prognostic Biomarker -
- Exploring the FORCE™ Platform for Targeted Therapies -
Dyne Therapeutics, Inc. (NASDAQ: DYN), a company devoted to advancing innovative therapeutics for genetically driven neuromuscular diseases, has recently shared exciting news regarding their upcoming presentations at the prestigious 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. This event is scheduled to take place in Dallas, Texas, and virtually from March 16-19. Dyne will share two oral presentations and five poster presentations, showcasing the promising results of their ongoing clinical trials.
Key Oral Presentations to Watch
On March 19, attendees will have the opportunity to hear directly from leading experts in the field during two significant oral presentations. These will cover vital findings from Dyne's ongoing clinical research in developing therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).
DELIVER Clinical Trial - A Closer Look
The first presentation will focus on the DELIVER clinical trial, which is currently examining the safety and efficacy of DYNE-251, directed at males with DMD mutations that are open to exon 51 skipping. Kevin Flanigan M.D., the Director at the Center for Gene Therapy at Nationwide Children's Hospital, will present these findings, offering insights on March 19th at 8:30 a.m. CT.
Insights from the ACHIEVE Trial
The second oral presentation will illuminate the data from the ACHIEVE trial, pertaining to the treatment of adults with DM1 utilizing DYNE-101. This session, presented by neurologist James Lilleker M.D., will begin at 12:30 p.m. CT on the same day.
Informative Poster Presentations
In addition to the oral presentations, Dyne will showcase five poster presentations that delve into various aspects of their research:
- Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping.
- Safety and Efficacy of DYNE-101 in Adults with DM1: Findings from the Phase 1/2 ACHIEVE Trial.
- Characteristics of Patients with Myotonic Dystrophy Type 1 with Complex Care Needs: Results from the Real-World IMPaCT Study.
- The FORCE™ Platform and its Impact on DUX4 Suppression and Muscle Function in Facioscapulohumeral Muscular Dystrophy Mouse Model.
- Enabling TfR1-mediated Delivery of Exon Skipping PMO to the CNS Using the FORCE™ Platform.
These presentations are set to take place during the poster sessions from 6:00 p.m. to 8:00 p.m. CT, from March 16 through March 18, in the conference's exhibit hall.
Special Symposium: Harnessing the FORCE™ Platform
Furthermore, Dyne will host a symposium titled “Harnessing the FORCE™ Platform to Advance Targeted Therapies for Neuromuscular Diseases” on March 18 at noon. This session aims to dive deep into the platform's capabilities and the significant advancements in their clinical programs for DMD and DM1.
About Dyne Therapeutics
Dyne Therapeutics is dedicated to the discovery and advancement of therapeutics that have the potential to transform lives, particularly for those affected by genetically driven neuromuscular disorders. Utilizing their innovative FORCE™ platform, Dyne is developing targeted treatment solutions that have shown promise in reaching muscle tissue and the central nervous system (CNS). Their robust pipeline encompasses ongoing clinical programs for DM1 and DMD, and preclinical initiatives for conditions such as facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
For additional insights and updates, visit Dyne’s official website and stay tuned for their presentations during the exciting 2025 MDA Conference.
Frequently Asked Questions
What is the focus of the presentations at the MDA Conference?
The presentations will highlight innovative research on treatments for DMD and DM1 through ongoing clinical trials.
Who are the presenters during the oral sessions?
Kevin Flanigan, M.D., will discuss the DELIVER trial, while James Lilleker, M.D., will present findings from the ACHIEVE trial.
When will the symposium on the FORCE™ platform take place?
The symposium is scheduled for March 18 at 12:00 p.m. CT.
How does Dyne Therapeutics develop its therapies?
Dyne Therapeutics employs its FORCE™ platform to create targeted therapeutics aimed at effectively delivering treatments to the muscle and CNS.
What diseases are part of Dyne's research pipeline?
Dyne's pipeline includes clinical programs for DM1 and DMD, alongside preclinical work for FSHD and Pompe disease.
